Chinese General Practice ›› 2025, Vol. 28 ›› Issue (11): 1336-1341.DOI: 10.12114/j.issn.1007-9572.2024.0408
• Original Research • Previous Articles Next Articles
Received:
2024-08-03
Revised:
2024-11-10
Published:
2025-04-15
Online:
2025-02-06
Contact:
GU Tianwei
通讯作者:
顾天伟
作者简介:
徐浩负责临床数据收集、整理、分析,并撰写论文初稿;方达负责绘制图表并协助统计分析;周卫红负责体检人群的检测;毕艳完善论文的审校;顾天伟提出研究思路,设计研究方案,完善论文最终内容及审校,并对论文负责。
基金资助:
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0408
项目 | 未发生脂肪肝组(n=14 563) | 发生脂肪肝组(n=2 523) | t(χ2)值 | P值 |
---|---|---|---|---|
性别(男/女) | 7 624/6 939 | 1 837/686 | 364.226a | <0.001 |
年龄(岁) | 43.9±13.2 | 46.6±13.4 | -9.384 | <0.001 |
BMI(kg/m2) | 22.9±2.5 | 25.0±2.6 | -37.979 | <0.001 |
WC(cm) | 78.30±8.82 | 85.50±8.01 | -41.081 | <0.001 |
SBP(mmHg) | 124±17 | 129±17 | -14.368 | <0.001 |
DBP(mmHg) | 76±11 | 80±14 | -14.717 | <0.001 |
FBG(mmol/L) | 4.94±0.88 | 5.15±1.02 | -10.049 | <0.001 |
HbA1c(%) | 5.56±0.62 | 5.70±0.71 | -6.064 | <0.001 |
ALT(U/L) | 19.53±17.40 | 23.84±14.37 | -13.476 | <0.001 |
AST(U/L) | 19.92±10.62 | 20.63±6.79 | -3.243 | <0.001 |
TG(mmol/L) | 1.02±0.64 | 1.44±0.87 | -23.101 | <0.001 |
TC(mmol/L) | 4.61±0.87 | 4.71±0.91 | -4.986 | <0.001 |
HDL-C(mmol/L) | 1.46±0.37 | 1.24±0.30 | 32.485 | <0.001 |
LDL-C(mmol/L) | 2.68±0.73 | 2.84±0.75 | -10.105 | <0.001 |
VAI | 1.17±1.15 | 1.81±1.51 | -20.554 | <0.001 |
CVAI | 57.30±40.91 | 92.12±35.04 | -44.892 | <0.001 |
Table 1 Comparison of baseline clinical data between the fatty liver group and non-fatty liver group
项目 | 未发生脂肪肝组(n=14 563) | 发生脂肪肝组(n=2 523) | t(χ2)值 | P值 |
---|---|---|---|---|
性别(男/女) | 7 624/6 939 | 1 837/686 | 364.226a | <0.001 |
年龄(岁) | 43.9±13.2 | 46.6±13.4 | -9.384 | <0.001 |
BMI(kg/m2) | 22.9±2.5 | 25.0±2.6 | -37.979 | <0.001 |
WC(cm) | 78.30±8.82 | 85.50±8.01 | -41.081 | <0.001 |
SBP(mmHg) | 124±17 | 129±17 | -14.368 | <0.001 |
DBP(mmHg) | 76±11 | 80±14 | -14.717 | <0.001 |
FBG(mmol/L) | 4.94±0.88 | 5.15±1.02 | -10.049 | <0.001 |
HbA1c(%) | 5.56±0.62 | 5.70±0.71 | -6.064 | <0.001 |
ALT(U/L) | 19.53±17.40 | 23.84±14.37 | -13.476 | <0.001 |
AST(U/L) | 19.92±10.62 | 20.63±6.79 | -3.243 | <0.001 |
TG(mmol/L) | 1.02±0.64 | 1.44±0.87 | -23.101 | <0.001 |
TC(mmol/L) | 4.61±0.87 | 4.71±0.91 | -4.986 | <0.001 |
HDL-C(mmol/L) | 1.46±0.37 | 1.24±0.30 | 32.485 | <0.001 |
LDL-C(mmol/L) | 2.68±0.73 | 2.84±0.75 | -10.105 | <0.001 |
VAI | 1.17±1.15 | 1.81±1.51 | -20.554 | <0.001 |
CVAI | 57.30±40.91 | 92.12±35.04 | -44.892 | <0.001 |
变量 | 模型1 | 模型2 | 模型3 | |||
---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
VAI | ||||||
Q1 | 1.000 | 1.000 | 1.000 | |||
Q2 | 1.829(1.545~2.164) | <0.001 | 1.499(1.266~1.776) | <0.001 | 1.409(1.180~1.681) | <0.001 |
Q3 | 3.380(2.897~3.944) | <0.001 | 2.312(1.975~2.706) | <0.001 | 2.051(1.715~2.454) | <0.001 |
Q4 | 5.734(4.949~6.643) | <0.001 | 3.204(2.744~3.742) | <0.001 | 2.579(2.088~3.186) | <0.001 |
CVAI | ||||||
Q1 | 1.000 | 1.000 | 1.000 | |||
Q2 | 3.548(2.877~4.376) | <0.001 | 3.167(2.533~3.961) | <0.001 | 2.431(1.939~3.048) | <0.001 |
Q3 | 6.689(5.484~8.158) | <0.001 | 5.300(4.163~6.747) | <0.001 | 3.335(2.599~4.278) | <0.001 |
Q4 | 11.241(9.263~13.642) | <0.001 | 6.897(5.169~9.202) | <0.001 | 3.375(2.488~4.576) | <0.001 |
Table 2 Cox regression analysis of the correlation of VAI and CVAI with fatty liver development
变量 | 模型1 | 模型2 | 模型3 | |||
---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | |
VAI | ||||||
Q1 | 1.000 | 1.000 | 1.000 | |||
Q2 | 1.829(1.545~2.164) | <0.001 | 1.499(1.266~1.776) | <0.001 | 1.409(1.180~1.681) | <0.001 |
Q3 | 3.380(2.897~3.944) | <0.001 | 2.312(1.975~2.706) | <0.001 | 2.051(1.715~2.454) | <0.001 |
Q4 | 5.734(4.949~6.643) | <0.001 | 3.204(2.744~3.742) | <0.001 | 2.579(2.088~3.186) | <0.001 |
CVAI | ||||||
Q1 | 1.000 | 1.000 | 1.000 | |||
Q2 | 3.548(2.877~4.376) | <0.001 | 3.167(2.533~3.961) | <0.001 | 2.431(1.939~3.048) | <0.001 |
Q3 | 6.689(5.484~8.158) | <0.001 | 5.300(4.163~6.747) | <0.001 | 3.335(2.599~4.278) | <0.001 |
Q4 | 11.241(9.263~13.642) | <0.001 | 6.897(5.169~9.202) | <0.001 | 3.375(2.488~4.576) | <0.001 |
分层 | CVAI-Q1 | CVAI-Q2 | P值 | CVAI-Q3 | P值 | CVAI-Q4 | P值 |
---|---|---|---|---|---|---|---|
性别 | |||||||
男 | 1.00 | 1.98(1.22~3.21) | 0.006 | 2.53(1.57~4.07) | <0.001 | 4.12(2.57~6.58) | <0.001 |
女 | 1.00 | 1.34(0.88~2.06) | 0.174 | 1.54(0.78~3.07) | 0.215 | 2.54(1.20~5.38) | 0.015 |
年龄 | |||||||
18~<40岁 | 1.00 | 1.81(1.26~2.60) | 0.001 | 1.85(1.14~3.00) | 0.012 | 2.45(1.35~4.46) | 0.003 |
≥40岁 | 1.00 | 2.03(1.07~3.84) | 0.029 | 3.37(1.79~6.31) | <0.001 | 8.63(4.73~15.77) | <0.001 |
BMI | |||||||
正常(18~24 kg/m2) | 1.00 | 1.92(1.40~2.64) | <0.001 | 2.20(1.48~3.27) | <0.001 | 2.73(1.43~5.21) | 0.002 |
超重(>24 kg/m2) | 1.00 | 1.42(0.69~2.95) | 0.343 | 2.05(1.02~4.12) | 0.045 | 3.63(1.85~7.14) | <0.001 |
Table 3 A hierarchical analysis of the correlation between CVAI and fatty liver
分层 | CVAI-Q1 | CVAI-Q2 | P值 | CVAI-Q3 | P值 | CVAI-Q4 | P值 |
---|---|---|---|---|---|---|---|
性别 | |||||||
男 | 1.00 | 1.98(1.22~3.21) | 0.006 | 2.53(1.57~4.07) | <0.001 | 4.12(2.57~6.58) | <0.001 |
女 | 1.00 | 1.34(0.88~2.06) | 0.174 | 1.54(0.78~3.07) | 0.215 | 2.54(1.20~5.38) | 0.015 |
年龄 | |||||||
18~<40岁 | 1.00 | 1.81(1.26~2.60) | 0.001 | 1.85(1.14~3.00) | 0.012 | 2.45(1.35~4.46) | 0.003 |
≥40岁 | 1.00 | 2.03(1.07~3.84) | 0.029 | 3.37(1.79~6.31) | <0.001 | 8.63(4.73~15.77) | <0.001 |
BMI | |||||||
正常(18~24 kg/m2) | 1.00 | 1.92(1.40~2.64) | <0.001 | 2.20(1.48~3.27) | <0.001 | 2.73(1.43~5.21) | 0.002 |
超重(>24 kg/m2) | 1.00 | 1.42(0.69~2.95) | 0.343 | 2.05(1.02~4.12) | 0.045 | 3.63(1.85~7.14) | <0.001 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
聂倩,孟翠巧,刘焕欣,等. 不同肥胖指标及内脏脂肪指数对非酒精性脂肪肝预测价值的比较[J]. 中国老年学杂志,2024,44(6):1321-1325.
|
[12] |
王洪岩,刘宇鹏,付红梅,等. 内脏脂肪指数和脂质蓄积指数对非超重/肥胖者代谢相关脂肪性肝病的预测价值[J]. 中华健康管理学杂志,2023,17(11):848-853. DOI:10.3760/cma.j.cn115624-20230615-00375.
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
王丽娜,高鹏飞,曹帆,等. 不同性别人群非酒精性脂肪性肝病患病现况及影响因素分析[J]. 中国全科医学,2023,26(33):4143-4151.
|
[30] |
|
[1] | XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852. |
[2] | ZHANG Peng, LIU Lidi, ZHANG Ying, YANG Ziyu, LIU Changming, TANG Yijun, LIAO Xiaoyang, JIA Yu. Interpretation and Clinical Implications of the 2024 Italian Guidelines for the Management of Adult Individuals with Overweight and Obesity and Metabolic Comorbidities That are Resistant to Behavioral Treatment [J]. Chinese General Practice, 2025, 28(30): 3747-3752. |
[3] | LU Donglei, YANG Fengying, FENG Zhanpeng, CAO Liquan, TAN Sijie. Conccurent Training Can Improve the Physical Health in Diabesity Individuals: a Meta-analysis [J]. Chinese General Practice, 2025, 28(27): 3410-3421. |
[4] | ZHAO Yuqing, WANG Wei, CHEN Liyuan, YOU Huijuan, WEI Ying, WANG Qinglu, YANG Fengying. Liver Macrophage Polarisation: a New Target for Exercise Prevention and Treatment of Non-alcoholic Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(27): 3456-3465. |
[5] | SHAO Xiaoying, SHAO Jie, ZHU Yan, SHAO Jinling, SHANG Ling, WU Zhenlian, ZHAO Yu, ZHANG Jiacai. Analysis of the Current Status of Iron Deficiency and Factors Affecting Iron Deficiency Anemia among Children Aged 6-36 Months in Guizhou Province [J]. Chinese General Practice, 2025, 28(27): 3368-3374. |
[6] | QUAN Jialin, ZHU Lin, SU Yu, CHEN Zekai, CHEN Ziqi, ZHANG Zhuofan. Research on the Improvement Effect of Exercise Modes on the Executive Function of Overweight or Obese Children or Adolescents: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(27): 3422-3431. |
[7] | ZHANG Yunuo, LI Ruibin, WANG Wei. Correlation Analysis of Serum Nesfatin-1 and Ghrelin Levels with Glycolipid Metabolism and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(26): 3264-3270. |
[8] | XIANG Xinyue, ZHANG Bingqing, OUYANG Yuqin, TANG Wenjuan, FENG Wenhuan. Impact of Short-term Medical Weight Loss on Atherosclerotic Cardiovascular Disease Risk in Patients with Obesity [J]. Chinese General Practice, 2025, 28(26): 3229-3239. |
[9] | WEI Yunhong, YANG Li, WANG Yulu, YE Qiufang, DAI Anni, HE Yan. Study on Cardiopulmonary Function During Different Exercise Stages in Patients with Obesity-related Hypertension [J]. Chinese General Practice, 2025, 28(24): 2972-2978. |
[10] | JIANG Shihua, ZHU Zheng, REN Yingying, ZHU Yaolei, WANG Yue, GAO Xibin. Meta Analysis of the Prevalence and Risk Factors of Myopia in Chinese Children and Adolescents [J]. Chinese General Practice, 2025, 28(24): 3043-3052. |
[11] | WU Sha, ZHANG Daiyi, LI Jin, XUAN Qinkao, QIAN Xiaodong, ZHU Chuanwu, PU Jianhong, ZHU Li. Correlation Analysis and Model Construction of Metabolic Associated Fatty Liver Disease and Hyperglycemia Based on a Health Examination Cohort [J]. Chinese General Practice, 2025, 28(23): 2861-2869. |
[12] | ZHOU Qian, WU Xiaomin, WANG Baohua, YAN Ruohan, YU Miao, WU Jing. Study on Nomogram Prediction Model for Risk of Gastric Cancer [J]. Chinese General Practice, 2025, 28(23): 2870-2877. |
[13] | LIU Yueying, WANG Xueli, LIU Yuqiu, WEI Limin. Correlation of Fasting C-peptide to Diabetes Duration Ration and Type 2 Diabetes Mellitus Combined with Metabolism-related Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2852-2860. |
[14] | WANG Peng, QIU Lixia, XU Shanshan, ZHANG Yang, ZHANG Jing, DU Xiaofei. Advances in the Co-management of Metabolism Dysfunction-associated Fatty Liver Disease and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(23): 2846-2851. |
[15] | BAI Xue, CHEN Qianqian, LI Jie. Innovative Practices in Chronic Disease Management: a New Model for Generalist-Specialist Combination Management of Diabetes and Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2841-2845. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||